Objective: This study evaluated the use of bioactive glass, PerioGlas, after retrograde filling with Super EBA cement in the treatment of periapical bone destruction.
Study design: Healing outcomes were followed up after endodontic surgery in 186 teeth. Outcomes were divided into two groups according to follow-up time: short- and long-term. The EBA group (n = 110) underwent endodontic surgery and retrograde filling with EBA cement. In the EBA + PerioGlas group (n = 76), PerioGlas was embedded in the bone cavity after retrograde filling.
Results: The success rate in the EBA + PerioGlas group was 72% compared with 56% in the Super EBA group at the short-term follow-up and 74% and 84%, respectively, at the long-term follow-up. Healing of periapical bone destruction classified as uncertain at the short-term follow-up was considered successful in two out of three cases at the long-term follow-up.
Conclusion: This study found that PerioGlas as bone substitute did not significantly improve endodontic healing outcome.